Fulcrum Therapeutics Unveils New Clinical Data from Pociredir PIONEER Trial in Sickle Cell Disease
Fulcrum Therapeutics Inc. will host an investor event on December 7, 2025, to review new clinical data from the Phase 1b PIONEER trial of pociredir in sickle cell disease. The event will present initial data from the 20 mg dose cohort and full data from the 12 mg dose cohort, also to be shared at the 67th ASH Annual Meeting. A replay will be available on Fulcrum’s website.
Fulcrum Therapeutics Inc. announced it will host an investor event on December 7, 2025, to review new clinical data from the Phase 1b PIONEER trial of pociredir in sickle cell disease. The event will include initial clinical data from the 20 mg dose cohort and full data from the 12 mg dose cohort. These results will also be presented at the 67th American Society of Hematology (ASH) Annual Meeting. A replay of the event will be available on Fulcrum’s website following the presentation. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fulcrum Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9595265-en) on December 02, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
